title: Insight into pimecrolimus experience in seborrheic dermatitis: close follow-up with exact mean cure and remission times and side-effect profile.
abstract: BACKGROUND
  Pimecrolimus was found to be effective for the treatment of seborrheic dermatitis in several studies and its off-label use is increasing gradually.
  
  
  OBJECTIVE
  This study was conducted to obtain more detailed information concerning the daily use of pimecrolimus in seborrheic dermatitis and it also aims to contribute to data for the future construction of guidelines.
  
  
  METHODS
  A total of 52 patients with seborrheic dermatitis enrolled in the study. Pimecrolimus 1% cream was applied twice daily. The mean cure and remission times, detailed responses of each clinical finding and side effects were investigated.
  
  
  RESULTS
  The mean cure and mean remission times were 13.34 and 47.98 days, respectively. Disease severity improved by 50% in between the third and seventh days. Pruritus responded first to pimecrolimus. The drug was equally effective for erythema and scaling. The most frequent side effect was the burning-tingling sensation. After the seventh day of the study, there was no side effect.
  
  
  CONCLUSIONS
  Pimecrolimus applications for the treatment of seborrheic dermatitis provide a complete cure in a short period of time and a sustained symptom-free period with low and self-limited side effects.
authors.affiliation: Department of Dermatology, Ministry of Health Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey. semihtatlican@gmail.com
authors.forename: Semih
authors.initials: S
authors.lastname: Tatlican
authors.forename: Cemile
authors.initials: C
authors.lastname: Eren
authors.forename: Fatma
authors.initials: F
authors.lastname: Eskioglu
mesh_terms: D000328:Adult; D012628:Dermatitis, Seborrheic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011537:Pruritus / Q000188:drug therapy; D016559:Tacrolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D003879:Dermatologic Agents; C117268:pimecrolimus; D016559:Tacrolimus